Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
暂无分享,去创建一个
M. Kurosumi | S. Kurozumi | H. Matsumoto | Kenichi Inoue | T. Fujii | J. Horiguchi | T. Oyama | K. Shirabe